-
1
-
-
79952232216
-
Global cancer statistics
-
A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
2
-
-
69249209651
-
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
-
M.J Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
-
(2009)
Eur Urol
, vol.56
, pp. 584-591
-
-
Roobol, M.J.1
Kerkhof, M.2
Schröder, F.H.3
-
3
-
-
63249118690
-
Screening and prostate-cancer mortality in a randomized European study
-
F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
-
(2009)
N Engl J Med
, vol.360
, pp. 1320-1328
-
-
Schröder, F.H.1
Hugosson, J.2
Roobol, M.J.3
-
4
-
-
77955279420
-
Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
-
J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
-
(2010)
Lancet Oncol
, vol.11
, pp. 725-732
-
-
Hugosson, J.1
Carlsson, S.2
Aus, G.3
-
5
-
-
70649106303
-
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
-
E.A. Heijnsdijk, A. der Kinderen, E.M. Wever, G. Draisma, M.J. Roobol, and H.J. de Koning Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br J Cancer 101 2009 1833 1838
-
(2009)
Br J Cancer
, vol.101
, pp. 1833-1838
-
-
Heijnsdijk, E.A.1
Der Kinderen, A.2
Wever, E.M.3
Draisma, G.4
Roobol, M.J.5
De Koning, H.J.6
-
6
-
-
0038275923
-
Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European randomized study of screening for prostate cancer
-
G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878 (Pubitemid 36833878)
-
(2003)
Journal of the National Cancer Institute
, vol.95
, Issue.12
, pp. 868-878
-
-
Draisma, G.1
Boer, R.2
Otto, S.J.3
Van Der Cruijsen, I.W.4
Damhuis, R.A.M.5
Schroder, F.H.6
De Koning, H.J.7
-
7
-
-
70350457793
-
A framework for the identification of men at increased risk for prostate cancer
-
M.J. Roobol, F.H. Schröder, and E.D. Crawford A framework for the identification of men at increased risk for prostate cancer J Urol 182 2009 2112 2120
-
(2009)
J Urol
, vol.182
, pp. 2112-2120
-
-
Roobol, M.J.1
Schröder, F.H.2
Crawford, E.D.3
-
8
-
-
70449525320
-
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
-
M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
-
(2010)
Eur Urol
, vol.57
, pp. 79-85
-
-
Roobol, M.J.1
Steyerberg, E.W.2
Kranse, R.3
-
9
-
-
79959560114
-
Disease-specific survival of men with prostate cancer detected during the screening interval: Results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up
-
X. Zhu, P.J. van Leeuwen, and M. Bul Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up Eur Urol 60 2011 330 336
-
(2011)
Eur Urol
, vol.60
, pp. 330-336
-
-
Zhu, X.1
Van Leeuwen, P.J.2
Bul, M.3
-
10
-
-
77955635233
-
Cancer statistics, 2010
-
A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
11
-
-
0030635849
-
Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race
-
A.P. Polednak Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race Cancer 79 1997 99 103
-
(1997)
Cancer
, vol.79
, pp. 99-103
-
-
Polednak, A.P.1
-
12
-
-
0027937517
-
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases
-
W.A. Sakr, D.J. Grignon, and J.D. Crissman High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases In Vivo 8 1994 439 443
-
(1994)
In Vivo
, vol.8
, pp. 439-443
-
-
Sakr, W.A.1
Grignon, D.J.2
Crissman, J.D.3
-
13
-
-
0023191075
-
Cancer of the prostate: Epidemiology and aetiology
-
D.G. Zaridze, and P. Boyle Cancer of the prostate: epidemiology and aetiology Br J Urol 59 1987 493 502 (Pubitemid 17075363)
-
(1987)
British Journal of Urology
, vol.59
, Issue.6
, pp. 493-502
-
-
Zaridze, D.G.1
Boyle, P.2
-
14
-
-
57149118824
-
Defining increased future risk for prostate cancer: Evidence from a population based screening cohort
-
F.H. Schröder, M.J. Roobol, G.L. Andriole, and N. Fleshner Defining increased future risk for prostate cancer: evidence from a population based screening cohort J Urol 181 2009 69 74
-
(2009)
J Urol
, vol.181
, pp. 69-74
-
-
Schröder, F.H.1
Roobol, M.J.2
Andriole, G.L.3
Fleshner, N.4
-
15
-
-
84855177156
-
Identifying and characterizing "escapes" - Men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)
-
X. Zhu, P.J. van Leeuwen, M. Bul, C.H. Bangma, M.J. Roobol, and F.H. Schroder Identifying and characterizing "escapes" - men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam) Int J Cancer 129 2011 2847 2854
-
(2011)
Int J Cancer
, vol.129
, pp. 2847-2854
-
-
Zhu, X.1
Van Leeuwen, P.J.2
Bul, M.3
Bangma, C.H.4
Roobol, M.J.5
Schroder, F.H.6
-
16
-
-
8644256697
-
Human prostate cancer risk factors
-
DOI 10.1002/cncr.20408
-
D.G. Bostwick, H.B. Burke, and D. Djakiew Human prostate cancer risk factors Cancer 101 2004 2371 2490 (Pubitemid 39505434)
-
(2004)
Cancer
, vol.101
, Issue.10 SUPPL.
, pp. 2371-2490
-
-
Bostwick, D.G.1
Burke, H.B.2
Djakiew, D.3
Euling, S.4
Ho, S.-M.5
Landolph, J.6
Morrison, H.7
Sonawane, B.8
Shifflett, T.9
Waters, D.J.10
Timms, B.11
-
17
-
-
0036190771
-
Role of family history and ethnicity on the mode and age of prostate cancer presentation
-
DOI 10.1002/pros.10051
-
M.P. Cotter, R.W. Gern, G.Y. Ho, R.Y. Chang, and R.D. Burk Role of family history and ethnicity on the mode and age of prostate cancer presentation Prostate 50 2002 216 221 (Pubitemid 34184660)
-
(2002)
Prostate
, vol.50
, Issue.4
, pp. 216-221
-
-
Cotter, M.P.1
Gern, R.W.2
Ho, G.Y.F.3
Chang, R.Y.4
Burk, R.D.5
-
18
-
-
33646459214
-
Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial
-
DOI 10.1093/jnci/djj131
-
I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534 (Pubitemid 43898816)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.8
, pp. 529-534
-
-
Thompson, I.M.1
Ankerst, D.P.2
Chi, C.3
Goodman, P.J.4
Tangen, C.M.5
Lucia, M.S.6
Feng, Z.7
Parnes, H.L.8
Coltman Jr., C.A.9
-
19
-
-
0344874632
-
Populations at high risk for prostate cancer
-
DOI 10.1016/S0094-0143(03)00058-2
-
K. Hsieh, and P.C. Albertsen Populations at high risk for prostate cancer Urol Clin North Am 30 2003 669 676 (Pubitemid 37485184)
-
(2003)
Urologic Clinics of North America
, vol.30
, Issue.4
, pp. 669-676
-
-
Hsieh, K.1
Albertsen, P.C.2
-
20
-
-
0242268868
-
Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis
-
DOI 10.1002/ijc.11466
-
D.W. Bruner, D. Moore, A. Parlanti, J. Dorgan, and P. Engstrom Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis Int J Cancer 107 2003 797 803 (Pubitemid 37339734)
-
(2003)
International Journal of Cancer
, vol.107
, Issue.5
, pp. 797-803
-
-
Bruner, D.W.1
Moore, D.2
Parlanti, A.3
Dorgan, J.4
Engstrom, P.5
-
21
-
-
0037635390
-
A systematic review and meta-analysis of familial prostate cancer risk
-
DOI 10.1046/j.1464-410X.2003.04232.x
-
L.E. Johns, and R.S. Houlston A systematic review and meta-analysis of familial prostate cancer risk BJU Int 91 2003 789 794 (Pubitemid 36724060)
-
(2003)
BJU International
, vol.91
, Issue.9
, pp. 789-794
-
-
Johns, L.E.1
Houlston, R.S.2
-
22
-
-
77955309014
-
Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members
-
A. Brandt, J.L. Bermejo, J. Sundquist, and K. Hemminki Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members Eur Urol 58 2010 275 280
-
(2010)
Eur Urol
, vol.58
, pp. 275-280
-
-
Brandt, A.1
Bermejo, J.L.2
Sundquist, J.3
Hemminki, K.4
-
23
-
-
34648846905
-
The impact of obesity on prostate cancer
-
J.G. van Roermund, and J.A. Witjes The impact of obesity on prostate cancer World J Urol 25 2007 491 497
-
(2007)
World J Urol
, vol.25
, pp. 491-497
-
-
Van Roermund, J.G.1
Witjes, J.A.2
-
24
-
-
79960273058
-
The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series
-
D.M. Moreira, T. Anderson, and L. Gerber The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series Cancer Causes Control 22 2011 977 983
-
(2011)
Cancer Causes Control
, vol.22
, pp. 977-983
-
-
Moreira, D.M.1
Anderson, T.2
Gerber, L.3
-
25
-
-
52049112114
-
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02
-
M.R. Smith, K. Bae, and J.A. Efstathiou Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02 J Clin Oncol 26 2008 4333 4339
-
(2008)
J Clin Oncol
, vol.26
, pp. 4333-4339
-
-
Smith, M.R.1
Bae, K.2
Efstathiou, J.A.3
-
26
-
-
80955165946
-
Diabetes and prostate cancer risk in the REDUCE trial
-
C. Wu, D.M. Moreira, L. Gerber, R.S. Rittmaster, G.L. Andriole, and S.J. Freedland Diabetes and prostate cancer risk in the REDUCE trial Prostate Cancer Prostatic Dis 14 2011 326 331
-
(2011)
Prostate Cancer Prostatic Dis
, vol.14
, pp. 326-331
-
-
Wu, C.1
Moreira, D.M.2
Gerber, L.3
Rittmaster, R.S.4
Andriole, G.L.5
Freedland, S.J.6
-
27
-
-
80052103055
-
Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy
-
C. De Nunzio, S.J. Freedland, and R. Miano Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy Prostate 71 2011 1492 1498
-
(2011)
Prostate
, vol.71
, pp. 1492-1498
-
-
De Nunzio, C.1
Freedland, S.J.2
Miano, R.3
-
28
-
-
79953328519
-
Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer
-
J. Flanagan, P.K. Gray, and N. Hahn Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer Ann Oncol 22 2011 801 807
-
(2011)
Ann Oncol
, vol.22
, pp. 801-807
-
-
Flanagan, J.1
Gray, P.K.2
Hahn, N.3
-
29
-
-
68449101818
-
Components of the metabolic syndrome and risk of prostate cancer: The HUNT 2 cohort, Norway
-
R.M. Martin, L. Vatten, D. Gunnell, P. Romundstad, and T.I. Nilsen Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway Cancer Causes Control 20 2009 1181 1192
-
(2009)
Cancer Causes Control
, vol.20
, pp. 1181-1192
-
-
Martin, R.M.1
Vatten, L.2
Gunnell, D.3
Romundstad, P.4
Nilsen, T.I.5
-
30
-
-
79952075128
-
Comorbidity and mortality results from a randomized prostate cancer screening trial
-
E.D. Crawford, R. Grubb III, and A. Black Comorbidity and mortality results from a randomized prostate cancer screening trial J Clin Oncol 29 2010 355 361
-
(2010)
J Clin Oncol
, vol.29
, pp. 355-361
-
-
Crawford, E.D.1
Grubb Iii, R.2
Black, A.3
-
31
-
-
80053920100
-
Comorbidity and competing risks for mortality in men with prostate cancer
-
T.J. Daskivich, K. Chamie, and L. Kwan Comorbidity and competing risks for mortality in men with prostate cancer Cancer 117 2011 4642 4650
-
(2011)
Cancer
, vol.117
, pp. 4642-4650
-
-
Daskivich, T.J.1
Chamie, K.2
Kwan, L.3
-
32
-
-
79954428605
-
Impact of comorbidity on survival among men with localized prostate cancer
-
P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, H. Li, and G.L. Lu-Yao Impact of comorbidity on survival among men with localized prostate cancer J Clin Oncol 29 2011 1335 1341
-
(2011)
J Clin Oncol
, vol.29
, pp. 1335-1341
-
-
Albertsen, P.C.1
Moore, D.F.2
Shih, W.3
Lin, Y.4
Li, H.5
Lu-Yao, G.L.6
-
33
-
-
0034796225
-
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop?
-
B. Djavan, V. Ravery, and A. Zlotta Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 2001 1679 1683
-
(2001)
J Urol
, vol.166
, pp. 1679-1683
-
-
Djavan, B.1
Ravery, V.2
Zlotta, A.3
-
34
-
-
4544248276
-
Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (reduce) trial
-
DOI 10.1097/01.ju.0000139320.78673.2a
-
G. Andriole, D. Bostwick, and O. Brawley Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial J Urol 172 2004 1314 1317 (Pubitemid 39249705)
-
(2004)
Journal of Urology
, vol.172
, Issue.4
, pp. 1314-1317
-
-
Andriole, G.1
Bostwick, D.2
Brawley, O.3
Gomella, L.4
Marberger, M.5
Tindall, D.6
Breed, S.7
Somerville, M.8
Rittmaster, R.9
-
35
-
-
58849157659
-
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy
-
J.L. Campos-Fernandes, L. Bastien, and N. Nicolaiew Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy Eur Urol 55 2009 600 609
-
(2009)
Eur Urol
, vol.55
, pp. 600-609
-
-
Campos-Fernandes, J.L.1
Bastien, L.2
Nicolaiew, N.3
-
36
-
-
0025849053
-
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
-
W.J. Catalona, D.S. Smith, and T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
-
(1991)
N Engl J Med
, vol.324
, pp. 1156-1161
-
-
Catalona, W.J.1
Smith, D.S.2
Ratliff, T.L.3
-
37
-
-
0023233060
-
Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate
-
T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, and E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916 (Pubitemid 17147932)
-
(1987)
New England Journal of Medicine
, vol.317
, Issue.15
, pp. 909-916
-
-
Stamey, T.A.1
Yang, N.2
Hay, A.R.3
-
38
-
-
0030913316
-
Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: Enhancement of specificity with free PSA measurements
-
W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455 (Pubitemid 27208887)
-
(1997)
Journal of the American Medical Association
, vol.277
, Issue.18
, pp. 1452-1455
-
-
Catalona, W.J.1
Smith, D.S.2
Ornstein, D.K.3
-
39
-
-
21444447966
-
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower
-
DOI 10.1001/jama.294.1.66
-
I.M. Thompson, D.P. Ankerst, and C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 2005 66 70 (Pubitemid 41002840)
-
(2005)
Journal of the American Medical Association
, vol.294
, Issue.1
, pp. 66-70
-
-
Thompson, I.M.1
Ankerst, D.P.2
Chi, C.3
Lucia, M.S.4
Goodman, P.J.5
Crowley, J.J.6
Parnes, H.L.7
Coltman Jr., C.A.8
-
40
-
-
0027972144
-
1-antichymotrypsin before diagnosis of prostate cancer
-
DOI 10.1016/S0140-6736(94)90405-7
-
U.H. Stenman, M. Hakama, P. Knekt, A. Aromaa, L. Teppo, and J. Leinonen Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer Lancet 344 1994 1594 1598 (Pubitemid 24365358)
-
(1994)
Lancet
, vol.344
, Issue.8937
, pp. 1594-1598
-
-
Stenman, U.-H.1
Hakama, M.2
Knekt, P.3
Aromaa, A.4
Teppo, L.5
Leinonen, J.6
-
41
-
-
0028801975
-
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
-
P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
-
(1995)
JAMA
, vol.273
, pp. 289-294
-
-
Gann, P.H.1
Hennekens, C.H.2
Stampfer, M.J.3
-
42
-
-
0034875454
-
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: Results from the Baltimore Longitudinal Study of Aging
-
DOI 10.1016/S0090-4295(01)01304-8, PII S0090429501013048
-
J. Fang, E.J. Metter, P. Landis, D.W. Chan, C.H. Morrell, and H.B. Carter Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging Urology 58 2001 411 416 (Pubitemid 32816360)
-
(2001)
Urology
, vol.58
, Issue.3
, pp. 411-416
-
-
Fang, J.1
Metter E.Jeffrey2
Landis, P.3
Chan, D.W.4
Morrell, C.H.5
Carter H.Ballentine6
-
43
-
-
3242759906
-
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study
-
DOI 10.1097/01.ju.0000132133.10470.bb
-
J.A. Antenor, M. Han, K.A. Roehl, R.B. Nadler, and W.J. Catalona Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study J Urol 172 2004 90 93 (Pubitemid 41615045)
-
(2004)
Journal of Urology
, vol.172
, Issue.1
, pp. 90-93
-
-
Antenor, J.A.V.1
Han, M.2
Roehl, K.A.3
Nadler, R.B.4
Catalona, W.J.5
-
44
-
-
31944436853
-
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old
-
DOI 10.1016/j.urology.2005.08.040, PII S0090429505011970
-
S. Loeb, K.A. Roehl, J.A. Antenor, W.J. Catalona, B.K. Suarez, and R.B. Nadler Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Urology 67 2006 316 320 (Pubitemid 43189848)
-
(2006)
Urology
, vol.67
, Issue.2
, pp. 316-320
-
-
Loeb, S.1
Roehl, K.A.2
Antenor, J.A.V.3
Catalona, W.J.4
Suarez, B.K.5
Nadler, R.B.6
-
45
-
-
79952133146
-
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50
-
H. Lilja, A.M. Cronin, and A. Dahlin Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 2011 1210 1219
-
(2011)
Cancer
, vol.117
, pp. 1210-1219
-
-
Lilja, H.1
Cronin, A.M.2
Dahlin, A.3
-
46
-
-
33846959137
-
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
-
DOI 10.1200/JCO.2006.06.9351
-
H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436 (Pubitemid 350002992)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.4
, pp. 431-436
-
-
Lilja, H.1
Ulmert, D.2
Bjork, T.3
Becker, C.4
Serio, A.M.5
Nilsson, J.-A.6
Abrahamsson, P.-A.7
Vickers, A.J.8
Berglund, G.9
-
47
-
-
41149091657
-
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
-
D. Ulmert, A.M. Cronin, and T. Bjork Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study BMC Med 6 2008 6
-
(2008)
BMC Med
, vol.6
, pp. 6
-
-
Ulmert, D.1
Cronin, A.M.2
Bjork, T.3
-
48
-
-
77956811462
-
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
-
A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
-
(2010)
BMJ
, vol.341
, pp. 4521
-
-
Vickers, A.J.1
Cronin, A.M.2
Bjork, T.3
-
49
-
-
79952282237
-
Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam
-
M. Bul, P.J. van Leeuwen, X. Zhu, F.H. Schröder, and M.J. Roobol Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam Eur Urol 59 2011 498 505
-
(2011)
Eur Urol
, vol.59
, pp. 498-505
-
-
Bul, M.1
Van Leeuwen, P.J.2
Zhu, X.3
Schröder, F.H.4
Roobol, M.J.5
-
50
-
-
25144500004
-
Individualized screening interval for prostate cancer based on prostate-specific antigen level: Results of a prospective, randomized, population-based study
-
DOI 10.1001/archinte.165.16.1857
-
G. Aus, J.E. Damber, A. Khatami, H. Lilja, J. Stranne, and J. Hugosson Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study Arch Intern Med 165 2005 1857 1861 (Pubitemid 41352080)
-
(2005)
Archives of Internal Medicine
, vol.165
, Issue.16
, pp. 1857-1861
-
-
Aus, G.1
Damber, J.-E.2
Khatami, A.3
Lilja, H.4
Stranne, J.5
Hugosson, J.6
-
51
-
-
13844264517
-
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam)
-
DOI 10.1016/j.urology.2004.09.046
-
M.J. Roobol, D.W. Roobol, and F.H. Schröder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346 (Pubitemid 40248025)
-
(2005)
Urology
, vol.65
, Issue.2
, pp. 343-346
-
-
Roobol, M.J.1
Roobol, D.W.2
Schroder, F.H.3
-
52
-
-
78049479383
-
Balancing the harms and benefits of early detection of prostate cancer
-
P.J. van Leeuwen, D. Connolly, and T.L. Tammela Balancing the harms and benefits of early detection of prostate cancer Cancer 116 2010 4857 4865
-
(2010)
Cancer
, vol.116
, pp. 4857-4865
-
-
Van Leeuwen, P.J.1
Connolly, D.2
Tammela, T.L.3
-
53
-
-
0038558404
-
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
-
DOI 10.1002/ijc.11074
-
S.J. Otto, I.W. van der Cruijsen, and M.K. Liem Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer Int J Cancer 105 2003 394 399 (Pubitemid 36570054)
-
(2003)
International Journal of Cancer
, vol.105
, Issue.3
, pp. 394-399
-
-
Otto, S.J.1
Van Der Cruijsen, I.W.2
Liem, M.K.3
Korfage, I.J.4
Lous, J.J.5
Schroder, F.H.6
De Koning, H.J.7
-
54
-
-
64349085837
-
Risk of developing prostate cancer in the future: Overview of prognostic biomarkers
-
N.E. Fleshner, and N. Lawrentschuk Risk of developing prostate cancer in the future: overview of prognostic biomarkers Urology 73 2009 S21 S27
-
(2009)
Urology
, vol.73
-
-
Fleshner, N.E.1
Lawrentschuk, N.2
-
55
-
-
0028256194
-
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
-
W.J. Catalona, J.P. Richie, and F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol 151 1994 1283 1290 (Pubitemid 24121936)
-
(1994)
Journal of Urology
, vol.151
, Issue.5
, pp. 1283-1290
-
-
Catalona, W.J.1
Richie, J.P.2
Ahmann, F.R.3
Hudson, M.A.4
Scardino, P.T.5
Flanigan, R.C.6
DeKernion, J.B.7
Ratliff, T.L.8
Kavoussi, L.R.9
Dalkin, B.L.10
Waters, W.B.11
MacFarlane, M.T.12
Southwick, P.C.13
-
56
-
-
37349005496
-
Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only
-
DOI 10.1016/j.urology.2007.07.019, PII S009042950701833X
-
O.T. Okotie, K.A. Roehl, M. Han, S. Loeb, S.N. Gashti, and W.J. Catalona Characteristics of prostate cancer detected by digital rectal examination only Urology 70 2007 1117 1120 (Pubitemid 350297358)
-
(2007)
Urology
, vol.70
, Issue.6
, pp. 1117-1120
-
-
Okotie, O.T.1
Roehl, K.A.2
Han, M.3
Loeb, S.4
Gashti, S.N.5
Catalona, W.J.6
-
57
-
-
36349014841
-
Prostate volume and adverse prostate cancer features: Fact not artifact
-
DOI 10.1016/j.ejca.2007.09.022, PII S0959804907007459
-
A. Briganti, F.K. Chun, and N. Suardi Prostate volume and adverse prostate cancer features: fact not artifact Eur J Cancer 43 2007 2669 2677 (Pubitemid 350151846)
-
(2007)
European Journal of Cancer
, vol.43
, Issue.18
, pp. 2669-2677
-
-
Briganti, A.1
Chun, F.K.-H.2
Suardi, N.3
Gallina, A.4
Walz, J.5
Graefen, M.6
Shariat, S.7
Ebersdobler, A.8
Rigatti, P.9
Perrotte, P.10
Saad, F.11
Montorsi, F.12
Huland, H.13
Karakiewicz, P.I.14
-
58
-
-
85047699965
-
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study
-
DOI 10.1200/JCO.2005.05.025
-
S.J. Freedland, W.B. Isaacs, and E.A. Platz Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study J Clin Oncol 23 2005 7546 7554 (Pubitemid 46291818)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.30
, pp. 7546-7554
-
-
Freedland, S.J.1
Isaacs, W.B.2
Platz, E.A.3
Terris, M.K.4
Aronson, W.J.5
Amling, C.L.6
Presti Jr., J.C.7
Kane, C.J.8
-
59
-
-
70049104883
-
Screening: Should more biopsies be taken in larger prostates?
-
P. van Leeuwen, R. van den Bergh, T. Wolters, F. Schröder, and M. Roobol Screening: should more biopsies be taken in larger prostates? BJU Int 104 2009 919 924
-
(2009)
BJU Int
, vol.104
, pp. 919-924
-
-
Van Leeuwen, P.1
Van Den Bergh, R.2
Wolters, T.3
Schröder, F.4
Roobol, M.5
-
60
-
-
35648943184
-
High Yield of Saturation Prostate Biopsy for Patients with Previous Negative Biopsies and Small Prostates
-
DOI 10.1016/j.urology.2007.05.017, PII S0090429507006012
-
K.P. Sajadi, T. Kim, M.K. Terris, J.A. Brown, and R.W. Lewis High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates Urology 70 2007 691 695 (Pubitemid 350030213)
-
(2007)
Urology
, vol.70
, Issue.4
, pp. 691-695
-
-
Sajadi, K.P.1
Kim, T.2
Terris, M.K.3
Brown, J.A.4
Lewis, R.W.5
-
61
-
-
84856380113
-
Prediction of prostate cancer risk: The role of prostate volume and digital rectal examination in the ERSPC risk calculators
-
M.J. Roobol, H.A. Van Vugt, and S. Loeb Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators Eur Urol 61 2012 577 583
-
(2012)
Eur Urol
, vol.61
, pp. 577-583
-
-
Roobol, M.J.1
Van Vugt, H.A.2
Loeb, S.3
-
62
-
-
0026755373
-
Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease
-
H.B. Carter, C.H. Morrell, and J.D. Pearson Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease Cancer Res 52 1992 3323 3328
-
(1992)
Cancer Res
, vol.52
, pp. 3323-3328
-
-
Carter, H.B.1
Morrell, C.H.2
Pearson, J.D.3
-
63
-
-
0028787237
-
Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity
-
H.B. Carter, J.D. Pearson, and Z. Waclawiw Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity Urology 45 1995 591 596
-
(1995)
Urology
, vol.45
, pp. 591-596
-
-
Carter, H.B.1
Pearson, J.D.2
Waclawiw, Z.3
-
64
-
-
54449098163
-
PSA velocity is associated with Gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness
-
discussion 1120
-
S. Loeb, D.E. Sutherland, A.V. D'Amico, K.A. Roehl, and W.J. Catalona PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness Urology 72 2008 1116 1120 discussion 1120
-
(2008)
Urology
, vol.72
, pp. 1116-1120
-
-
Loeb, S.1
Sutherland, D.E.2
D'Amico, A.V.3
Roehl, K.A.4
Catalona, W.J.5
-
65
-
-
71249150273
-
Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
-
S. Loeb, K.A. Roehl, B.T. Helfand, D. Kan, and W.J. Catalona Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol 183 2010 112 116
-
(2010)
J Urol
, vol.183
, pp. 112-116
-
-
Loeb, S.1
Roehl, K.A.2
Helfand, B.T.3
Kan, D.4
Catalona, W.J.5
-
66
-
-
33750582502
-
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability
-
DOI 10.1093/jnci/djj410
-
H.B. Carter, L. Ferrucci, and A. Kettermann Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 2006 1521 1527 (Pubitemid 44680903)
-
(2006)
Journal of the National Cancer Institute
, vol.98
, Issue.21
, pp. 1521-1527
-
-
Carter, H.B.1
Ferrucci, L.2
Kettermann, A.3
Landis, P.4
Wright, E.J.5
Epstein, J.I.6
Trock, B.J.7
Metter, E.J.8
-
67
-
-
40849140583
-
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer
-
J.J. Meeks, C.S. Thaxton, S. Loeb, K.A. Roehl, B.T. Helfand, and W.J. Catalona Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer J Urol 179 2008 1340 1343
-
(2008)
J Urol
, vol.179
, pp. 1340-1343
-
-
Meeks, J.J.1
Thaxton, C.S.2
Loeb, S.3
Roehl, K.A.4
Helfand, B.T.5
Catalona, W.J.6
-
68
-
-
34250795026
-
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
-
DOI 10.1002/cncr.22737
-
A.V. D'Amico, M.H. Chen, W.J. Catalona, L. Sun, K.A. Roehl, and J.W. Moul Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors Cancer 110 2007 56 61 (Pubitemid 46986418)
-
(2007)
Cancer
, vol.110
, Issue.1
, pp. 56-61
-
-
D'Amico, A.V.1
Chen, M.-H.2
Catalona, W.J.3
Sun, L.4
Roehl, K.A.5
Moul, J.W.6
-
69
-
-
3042727071
-
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
-
A.V. D'Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
-
(2004)
N Engl J Med
, vol.351
, pp. 125-135
-
-
D'Amico, A.V.1
Chen, M.H.2
Roehl, K.A.3
Catalona, W.J.4
-
70
-
-
39749180009
-
Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
-
DOI 10.1200/JCO.2007.13.1490
-
D. Ulmert, A.M. Serio, and M.F. O'Brien Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835 841 (Pubitemid 351398073)
-
(2008)
Journal of Clinical Oncology
, vol.26
, Issue.6
, pp. 835-841
-
-
Ulmert, D.1
Serio, A.M.2
O'Brien, M.F.3
Becker, C.4
Eastham, J.A.5
Scardino, P.T.6
Bjork, T.7
Berglund, G.8
Vickers, A.J.9
Lilja, H.10
-
71
-
-
34247162236
-
Prostate-specific antigen velocity and prostate cancer gleason grade and stage
-
DOI 10.1002/cncr.22558
-
P.F. Pinsky, G. Andriole, and E.D. Crawford Prostate-specific antigen velocity and prostate cancer Gleason grade and stage Cancer 109 2007 1689 1695 (Pubitemid 46595706)
-
(2007)
Cancer
, vol.109
, Issue.8
, pp. 1689-1695
-
-
Pinsky, P.F.1
Andriole, G.2
Crawford, E.D.3
Chia, D.4
Kramer, B.S.5
Grubb, R.6
Greenlee, R.7
Gohagan, J.K.8
-
72
-
-
1242296763
-
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (ROTTERDAM)
-
DOI 10.1016/j.urology.2003.09.083
-
M.J. Roobol, R. Kranse, H.J. de Koning, and F.H. Schroder Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM) Urology 63 2004 309 313 discussion 313-5 (Pubitemid 38234425)
-
(2004)
Urology
, vol.63
, Issue.2
, pp. 309-313
-
-
Roobol, M.J.1
Kranse, R.2
De Koning, H.J.3
Schroder, F.H.4
-
73
-
-
32944463469
-
Does PSA velocity predict prostate cancer in pre-screened populations?
-
DOI 10.1016/j.eururo.2005.12.026, PII S0302283805008419
-
F.H. Schröder, M.J. Roobol, T.H. van der Kwast, R. Kranse, and C.H. Bangma Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49 2006 460 465 discussion 465 (Pubitemid 43259552)
-
(2006)
European Urology
, vol.49
, Issue.3
, pp. 460-465
-
-
Schroder, F.H.1
Roobol, M.J.2
Van Der Kwast, T.H.3
Kranse, R.4
Bangma, C.H.5
-
74
-
-
70349295163
-
Prostate-specific antigen velocity for early detection of prostate cancer: Result from a large, representative, population-based cohort
-
A.J. Vickers, T. Wolters, and C.J. Savage Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort Eur Urol 56 2009 753 760
-
(2009)
Eur Urol
, vol.56
, pp. 753-760
-
-
Vickers, A.J.1
Wolters, T.2
Savage, C.J.3
-
75
-
-
79952833310
-
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
-
A.J. Vickers, C. Till, C.M. Tangen, H. Lilja, and I.M. Thompson An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 462 469
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 462-469
-
-
Vickers, A.J.1
Till, C.2
Tangen, C.M.3
Lilja, H.4
Thompson, I.M.5
-
76
-
-
78049457613
-
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer
-
C.H. Bangma, R.H. van Schaik, B.G. Blijenberg, M.J. Roobol, H. Lilja, and U.H. Stenman On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer Eur J Cancer 46 2010 3109 3119
-
(2010)
Eur J Cancer
, vol.46
, pp. 3109-3119
-
-
Bangma, C.H.1
Van Schaik, R.H.2
Blijenberg, B.G.3
Roobol, M.J.4
Lilja, H.5
Stenman, U.H.6
-
77
-
-
79953777963
-
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range
-
W.J. Catalona, A.W. Partin, and M.G. Sanda A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range J Urol 185 2011 1650 1655
-
(2011)
J Urol
, vol.185
, pp. 1650-1655
-
-
Catalona, W.J.1
Partin, A.W.2
Sanda, M.G.3
-
78
-
-
79959554692
-
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting
-
G. Guazzoni, L. Nava, and M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA Between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214 222
-
(2011)
Eur Urol
, vol.60
, pp. 214-222
-
-
Guazzoni, G.1
Nava, L.2
Lazzeri, M.3
-
79
-
-
77949277570
-
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study
-
B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355 1359
-
(2010)
J Urol
, vol.183
, pp. 1355-1359
-
-
Le, B.V.1
Griffin, C.R.2
Loeb, S.3
-
80
-
-
77951621115
-
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
-
F.H. Jansen, R.H.N. van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
-
(2010)
Eur Urol
, vol.57
, pp. 921-927
-
-
Jansen, F.H.1
Van Schaik, R.H.N.2
Kurstjens, J.3
-
81
-
-
0035018273
-
The new human tissue kallikrein gene family: Structure, function, and association to disease
-
DOI 10.1210/er.22.2.184
-
G.M. Yousef, and E.P. Diamandis The new human tissue kallikrein gene family: structure, function, and association to disease Endocr Rev 22 2001 184 204 (Pubitemid 32458158)
-
(2001)
Endocrine Reviews
, vol.22
, Issue.2
, pp. 184-204
-
-
Yousef, G.M.1
Diamandis, E.P.2
-
82
-
-
0034185675
-
Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater
-
C. Becker, T. Piironen, K. Pettersson, J. Hugosson, and H. Lilja Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater Urology 55 2000 694 699
-
(2000)
Urology
, vol.55
, pp. 694-699
-
-
Becker, C.1
Piironen, T.2
Pettersson, K.3
Hugosson, J.4
Lilja, H.5
-
83
-
-
0033046353
-
Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases
-
DOI 10.1016/S0090-4295(98)00637-2, PII S0090429598006372
-
M.F. Darson, A. Pacelli, and P. Roche Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases Urology 53 1999 939 944 (Pubitemid 29196309)
-
(1999)
Urology
, vol.53
, Issue.5
, pp. 939-944
-
-
Darson, M.F.1
Pacelli, A.2
Roche, P.3
Rittenhouse, H.G.4
Wolfert, R.L.5
Saeid, M.S.6
Young, C.Y.F.7
Klee, G.G.8
Tindall, D.J.9
Bostwick, D.G.10
-
84
-
-
0032721585
-
Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis
-
DOI 10.1016/S0090-4295(99)00270-8, PII S0090429599002708
-
A.W. Partin, W.J. Catalona, and J.A. Finlay Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis Urology 54 1999 839 845 (Pubitemid 29505583)
-
(1999)
Urology
, vol.54
, Issue.5
, pp. 839-845
-
-
Partin, A.W.1
Catalona, W.J.2
Finlay, J.A.3
Darte, C.4
Tindall, D.J.5
Young, C.Y.-F.6
Klee, G.G.7
Chan, D.W.8
Rittenhouse, H.G.9
Wolfert, R.L.10
Woodrum, D.L.11
-
85
-
-
77953688557
-
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication
-
A. Vickers, A. Cronin, and M. Roobol Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
-
(2010)
J Clin Oncol
, vol.28
, pp. 2493-2498
-
-
Vickers, A.1
Cronin, A.2
Roobol, M.3
-
86
-
-
48249152185
-
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
-
A.J. Vickers, A.M. Cronin, and G. Aus A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden BMC Med 6 2008 19
-
(2008)
BMC Med
, vol.6
, pp. 19
-
-
Vickers, A.J.1
Cronin, A.M.2
Aus, G.3
-
87
-
-
79951626849
-
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening
-
A.J. Vickers, A. Gupta, and C.J. Savage A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening Cancer Epidemiol Biomarkers Prev 20 2011 255 261
-
(2011)
Cancer Epidemiol Biomarkers Prev
, vol.20
, pp. 255-261
-
-
Vickers, A.J.1
Gupta, A.2
Savage, C.J.3
-
88
-
-
0033429470
-
DD3: A new prostate-specific gene, highly overexpressed in prostate cancer
-
M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979 (Pubitemid 30004960)
-
(1999)
Cancer Research
, vol.59
, Issue.23
, pp. 5975-5979
-
-
Bussemakers, M.J.G.1
Van Bokhoven, A.2
Verhaegh, G.W.3
Smit, F.P.4
Karthaus, H.F.M.5
Schalken, J.A.6
Debruyne, F.M.J.7
Ru, N.8
Isaacs, W.B.9
-
89
-
-
33646942410
-
APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
-
DOI 10.1373/clinchem.2005.063289
-
J. Groskopf, S.M. Aubin, and I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089 1095 (Pubitemid 43794421)
-
(2006)
Clinical Chemistry
, vol.52
, Issue.6
, pp. 1089-1095
-
-
Groskopf, J.1
Aubin, S.M.J.2
Deras, I.L.3
Blase, A.4
Bodrug, S.5
Clark, C.6
Brentano, S.7
Mathis, J.8
Pham, J.9
Meyer, T.10
Cass, M.11
Hodge, P.12
Macairan, M.L.13
Marks, L.S.14
Rittenhouse, H.15
-
90
-
-
79955056992
-
Contemporary role of prostate cancer gene 3 in the management of prostate cancer
-
M.J. Roobol Contemporary role of prostate cancer gene 3 in the management of prostate cancer Curr Opin Urol 21 2011 225 229
-
(2011)
Curr Opin Urol
, vol.21
, pp. 225-229
-
-
Roobol, M.J.1
-
91
-
-
77956535473
-
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test
-
M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
-
(2010)
Eur Urol
, vol.58
, pp. 475-481
-
-
Roobol, M.J.1
Schröder, F.H.2
Van Leeuwen, P.3
-
92
-
-
54049139306
-
Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium
-
Z. Kote-Jarai, D.F. Easton, and J.L. Stanford Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium Cancer Epidemiol Biomarkers Prev 17 2008 2052 2061
-
(2008)
Cancer Epidemiol Biomarkers Prev
, vol.17
, pp. 2052-2061
-
-
Kote-Jarai, Z.1
Easton, D.F.2
Stanford, J.L.3
-
93
-
-
80051813565
-
A risk prediction algorithm based on family history and common genetic variants: Application to prostate cancer with potential clinical impact
-
R.J. Macinnis, A.C. Antoniou, and R.A. Eeles A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact Genet Epidemiol 35 2011 549 556
-
(2011)
Genet Epidemiol
, vol.35
, pp. 549-556
-
-
MacInnis, R.J.1
Antoniou, A.C.2
Eeles, R.A.3
-
94
-
-
50449098019
-
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer
-
author reply 1035-6
-
J. Ahn, S.I. Berndt, and S. Wacholder Variation in KLK genes, prostate-specific antigen and risk of prostate cancer Nat Genet 40 2008 1032 1034 author reply 1035-6
-
(2008)
Nat Genet
, vol.40
, pp. 1032-1034
-
-
Ahn, J.1
Berndt, S.I.2
Wacholder, S.3
-
95
-
-
77952026425
-
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: Kallikreins and prostate cancer
-
R.J. Klein, C. Hallden, and A.M. Cronin Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer Cancer Prev Res (Phila) 3 2010 611 619
-
(2010)
Cancer Prev Res (Phila)
, vol.3
, pp. 611-619
-
-
Klein, R.J.1
Hallden, C.2
Cronin, A.M.3
-
96
-
-
79957520906
-
Tumour markers in prostate cancer III: Biomarkers in urine
-
M.J. Roobol, A. Haese, and A. Bjartell Tumour markers in prostate cancer III: biomarkers in urine Acta Oncol 50 Suppl 1 2011 85 89
-
(2011)
Acta Oncol
, vol.50
, Issue.SUPPL. 1
, pp. 85-89
-
-
Roobol, M.J.1
Haese, A.2
Bjartell, A.3
-
97
-
-
45849109563
-
The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: A systematic review
-
F. Schröder, and M.W. Kattan The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review Eur Urol 54 2008 274 290
-
(2008)
Eur Urol
, vol.54
, pp. 274-290
-
-
Schröder, F.1
Kattan, M.W.2
-
98
-
-
71849102519
-
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection
-
S.J. Eyre, D.P. Ankerst, and J.T. Wei Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection J Urol 182 2009 2653 2658
-
(2009)
J Urol
, vol.182
, pp. 2653-2658
-
-
Eyre, S.J.1
Ankerst, D.P.2
Wei, J.T.3
-
99
-
-
60449108184
-
Predicting the outcome of prostate biopsy: Comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone
-
D.J. Hernandez, M. Han, and E.B. Humphreys Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone BJU Int 103 2009 609 614
-
(2009)
BJU Int
, vol.103
, pp. 609-614
-
-
Hernandez, D.J.1
Han, M.2
Humphreys, E.B.3
-
100
-
-
78651268239
-
The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients
-
T.C. Ngo, B.B. Turnbull, P.W. Lavori, and J.C. Presti Jr. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients J Urol 185 2011 483 487
-
(2011)
J Urol
, vol.185
, pp. 483-487
-
-
Ngo, T.C.1
Turnbull, B.B.2
Lavori, P.W.3
Presti, Jr.J.C.4
-
101
-
-
73749088254
-
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy
-
C.T. Nguyen, C. Yu, A. Moussa, M.W. Kattan, and J.S. Jones Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy J Urol 183 2010 529 533
-
(2010)
J Urol
, vol.183
, pp. 529-533
-
-
Nguyen, C.T.1
Yu, C.2
Moussa, A.3
Kattan, M.W.4
Jones, J.S.5
-
102
-
-
33845312324
-
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
-
DOI 10.1016/j.urology.2006.10.022, PII S0090429506024344
-
D.J. Parekh, D.P. Ankerst, and B.A. Higgins External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population Urology 68 2006 1152 1155 (Pubitemid 44880388)
-
(2006)
Urology
, vol.68
, Issue.6
, pp. 1152-1155
-
-
Parekh, D.J.1
Pauler Ankerst, D.2
Higgins, B.A.3
Hernandez, J.4
Canby-Hagino, E.5
Brand, T.6
Troyer, D.A.7
Leach, R.J.8
Thompson, I.M.9
-
103
-
-
80051646902
-
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators
-
R.K. Nam, M.W. Kattan, and J.L. Chin Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators J Clin Oncol 29 2011 2959 2964
-
(2011)
J Clin Oncol
, vol.29
, pp. 2959-2964
-
-
Nam, R.K.1
Kattan, M.W.2
Chin, J.L.3
-
104
-
-
55249102250
-
A graphical device to represent the outcomes of a logistic regression analysis
-
R. Kranse, M. Roobol, and F.H. Schröder A graphical device to represent the outcomes of a logistic regression analysis Prostate 68 2008 1674 1680
-
(2008)
Prostate
, vol.68
, pp. 1674-1680
-
-
Kranse, R.1
Roobol, M.2
Schröder, F.H.3
-
105
-
-
78650255605
-
Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators: A performance comparison in a contemporary screened cohort
-
V. Cavadas, L. Osório, F. Sabell, F. Teves, F. Branco, and M. Silva-Ramos Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators: a performance comparison in a contemporary screened cohort Eur Urol 58 2010 551 558
-
(2010)
Eur Urol
, vol.58
, pp. 551-558
-
-
Cavadas, V.1
Osório, L.2
Sabell, F.3
Teves, F.4
Branco, F.5
Silva-Ramos, M.6
-
106
-
-
79956368759
-
Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction
-
M. Oliveira, V. Marques, A.P. Carvalho, and A. Santos Head-to-head comparison of two online nomograms for prostate biopsy outcome prediction BJU Int 107 2011 1780 1783
-
(2011)
BJU Int
, vol.107
, pp. 1780-1783
-
-
Oliveira, M.1
Marques, V.2
Carvalho, A.P.3
Santos, A.4
-
107
-
-
80054016806
-
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
-
G. Trottier, M.J. Roobol, and N. Lawrentschuk Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort BJU Int 108 2011 E237 E244
-
(2011)
BJU Int
, vol.108
-
-
Trottier, G.1
Roobol, M.J.2
Lawrentschuk, N.3
-
108
-
-
79952985149
-
Prediction of prostate cancer in unscreened men: External validation of a risk calculator
-
H.A. van Vugt, M.J. Roobol, and R. Kranse Prediction of prostate cancer in unscreened men: external validation of a risk calculator Eur J Cancer 47 2011 903 909
-
(2011)
Eur J Cancer
, vol.47
, pp. 903-909
-
-
Van Vugt, H.A.1
Roobol, M.J.2
Kranse, R.3
-
109
-
-
34548507720
-
Assessing individual risk for prostate cancer
-
DOI 10.1200/JCO.2007.10.6450
-
R.K. Nam, A. Toi, and L.H. Klotz Assessing individual risk for prostate cancer J Clin Oncol 25 2007 3582 3588 (Pubitemid 47372595)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.24
, pp. 3582-3588
-
-
Nam, R.K.1
Toi, A.2
Klotz, L.H.3
Trachtenberg, J.4
Jewett, M.A.S.5
Appu, S.6
Loblaw, D.A.7
Sugar, L.8
Narod, S.A.9
Kattan, M.W.10
-
110
-
-
33750905259
-
Decision curve analysis: A novel method for evaluating prediction models
-
DOI 10.1177/0272989X06295361
-
A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Medical Decision Making 26 2006 565 574 (Pubitemid 44728772)
-
(2006)
Medical Decision Making
, vol.26
, Issue.6
, pp. 565-574
-
-
Vickers, A.J.1
Elkin, E.B.2
-
111
-
-
78649362120
-
EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease
-
A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
-
(2011)
Eur Urol
, vol.59
, pp. 61-71
-
-
Heidenreich, A.1
Bellmunt, J.2
Bolla, M.3
-
113
-
-
77949363162
-
American Cancer Society guideline for the early detection of prostate cancer: Update 2010
-
A.M. Wolf, R.C. Wender, and R.B. Etzioni American Cancer Society guideline for the early detection of prostate cancer: update 2010 CA Cancer J Clin 60 2010 70 98
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 70-98
-
-
Wolf, A.M.1
Wender, R.C.2
Etzioni, R.B.3
-
114
-
-
77649099098
-
NCCN clinical practice guidelines in oncology: Prostate cancer early detection
-
M.H Kawachi, R.R. Bahnson, and M. Barry NCCN clinical practice guidelines in oncology: prostate cancer early detection J Natl Compr Canc Netw 8 2010 240 262
-
(2010)
J Natl Compr Canc Netw
, vol.8
, pp. 240-262
-
-
Kawachi, M.H.1
Bahnson, R.R.2
Barry, M.3
|